CDX-1401: Phase I/II started

Celldex began an open-label, dose-escalation, U.S. Phase I/II trial in about 36 patients to evaluate 3 dosages of subcutaneous CDX-1401 given every 2 weeks for 4 doses in combination with resiquimod, ...